Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-DM1 and Pertuzumab in Early-stage HER2-positive Breast Cancer
NCT02326974Phase 2Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jan 2015
- Primary completion
- Jun 2018
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab emtansine in breast cancer, sponsored by Dana-Farber Cancer Institute. Started Jan 2015; status: active, not recruiting.
02
Drugs
trastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02326974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02326974.